Listed by the USPTO as LEONARD, ARTHUR S
Tech Center 1700 • Art Units: 1631 1633 1643 1651 1798
This examiner grants 50% of resolved cases
Arthur S. Leonard is a USPTO patent examiner in tech center 1700 and art unit 1631. The profile records 524 resolved cases, with a 50.4% allowance rate. The median time to allowance is 1261 days, indicating that applicants should plan for extended prosecution.
Interviews are associated with a 50.5% lift in allowance outcomes. The leading companies are University of Massachusetts, Massachusetts Institute of Technology, and Ramot At Tel-aviv University Ltd. The leading firms are BIRCH STEWART KOLASCH & BIRCH, LLP, MARSHALL, GERSTEIN & BORUN LLP, and MEDLEN & CARROLL, LLP. Interview preparation may be especially relevant when developing the response strategy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18448499 | KIT FOR PRODUCING ADENO-ASSOCIATED VIRUS, AND USE THEREOF | Final Rejection | FUJIFILM Corporation |
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17865375 | Programmable Modification of DNA | Final Rejection | Massachusetts Institute of Technology |
| 17831745 | DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR GENOME EDITING | Final Rejection | Massachusetts Institute of Technology |
| 18282645 | METHODS AND MATERIALS FOR TREATING PROPIONIC ACIDEMIA | Final Rejection | Mayo Foundation for Medical Education and Research |
| 18373569 | GENETICALLY MODIFIED GENES AND CELLS, AND METHODS OF USING SAME FOR SILENCING VIRUS GENE EXPRESSION | Final Rejection | Wisconsin Alumni Research Foundation |
| 18372374 | METHOD OF PRODUCING A CELL POPULATION COMPRISING AN AMNION-DERIVED MESENCHYMAL STEM CELL | Final Rejection | KANEKA CORPORATION |
| 18484667 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Final Rejection | THE TEXAS A&M UNIVERSITY SYSTEM |
| 18547348 | VIRAL VECTOR-BASED GENE THERAPY FOR OCULAR CONDITIONS | Final Rejection | The Regents of the University of Colorado, A Body Corporate |
| 18994948 | RECOMBINANT AAV HAVING AAV CLADE D AND CLADE E CAPSIDS AND COMPOSITIONS CONTAINING SAME | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18670290 | COMPOSITIONS AND METHODS FOR TREATING B-LYMPHOID MALIGNANCIES | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18981653 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | Non-Final OA | INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES |
| 18972072 | HUMANIZED MOUSE MODELS FOR ASSESSING IMMUNE CELL THERAPY | Non-Final OA | The Jackson Laboratory |
| 18003093 | METHODS OF GENERATING AN ACTIVATION INDUCIBLE EXPRESSION SYSTEM IN IMMUNE CELLS | Final Rejection | St. Jude Children's Research Hospital, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy50.4% of resolved applications examined by Arthur S Leonard were allowed (524 resolved cases), compared with 28.0% across Art Unit 1631 over the last five years.
This examiner's interview lift is +50.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Arthur S Leonard took 1,261 days on average from filing to allowance.
Arthur S Leonard examines applications in Art Unit 1631 in Tech Center 1700 (Chemistry & Materials).